The game changers of this type of BC are three cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) already approved by the US Food and Drug Administration (palbociclib, ribociclib, and abemaciclib) in combination with ET for first-line therapy [6,7,8]. The gene discussed is CDK4; the disease is breast cancer.